Mini-Oral Session

[MO33] Mini-Oral Session 33　COVID-19 2

Sat. Feb 19, 2022 3:40 PM - 4:30 PM Room 4 (Room A, 2F, Kyoto International Conference Center)

Chair：Eiki Ichihara（Department of Allergy and Respiratory Medicine, Okayama University），Taiji Koyama（Department of Medical Oncology/Hematology, Kobe University）

+Add all to schedule

[MO33-1] Limited Increase in Antibody Titers following BNT162b2 for More than 3 Years after Final Dose of Anti-CD20 Antibody

^○Yohei Funakoshi¹, Kimikazu Yakushijin¹, Goh Ohji², Wataru Hojo³, Hironori Sakai³, Marika Watanabe¹, Sakuya Matsumoto¹, Yu Mizutani¹, Akihito Kitao¹, Yoshiharu Miyata⁴, Yasuyuki Saito⁵, Shinichiro Kawamoto⁶, Katsuya Yamamoto¹, Mitsuhiro Ito⁷, Meiko Nishimura¹, Yoshinori Imamura¹, Naomi Kiyota^1,8, Hiroshi Matsuoka⁴, Yasuko Mori⁹, Hironobu Minami^1,8 (1.Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, 2.Division of Infection Disease Therapeutics, Department of Microbiology and Infectious Diseases, Kobe University Hospital and Graduate School of Medicine, 3.R&D, Cellspect Co., Ltd., 4.BioResource Center, Kobe University Hospital, 5.Division of Molecular and Cellular Signaling, Kobe University Graduate School of Medicine, 6.Department of Transfusion Medicine and Cell Therapy, Kobe University Hospital, 7.Division of Medical Biophysics, Kobe University Graduate School of Health Sciences, 8.Cancer Center, Kobe University Hospital, 9.Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine)

[MO33-2] Safety and Immunogenicity of BNT162b2 for Patients Undergoing Chemotherapy for Solid Cancers in Japan

^○Yohei Funakoshi¹, Kimikazu Yakushijin¹, Goh Ohji², Wataru Hojo³, Hironori Sakai³, Ryo Takai⁴, Taku Nose¹, Shinya Ohata¹, Yoshiaki Nagatani¹, Taiji Koyama¹, Akihito Kitao¹, Meiko Nishimura¹, Yoshinori Imamura¹, Naomi Kiyota^1,5, Kenichi Harada⁶, Yugo Tanaka⁷, Yasuko Mori⁸, Hironobu Minami^1,5 (1.Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, 2.Division of Infection Disease Therapeutics, Department of Microbiology and Infectious Diseases, Kobe University Hospital and Graduate School of Medicine, 3.R&D, Cellspect Co., Ltd., 4.Division of Gastrointestinal Surgery, Department of Surgery, Kobe University Hospital and Graduate School of Medicine, 5.Cancer Center, Kobe University Hospital, 6.Division of Urology, Department of Surgery, Kobe University Hospital and Graduate School of Medicine, 7.Division of Thoracic Surgery, Department of Surgery, Kobe University Hospital and Graduate School of Medicine, 8.Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine)

[MO33-3] 2020年愛媛県院内がん登録からみるCOVID19流行下でのがん診療の変化

^○Makoto Hamada^1,2, Natsumi Yamashita^1,2, Yutsuko Ohhira^1,2, Norihiro Teramoto^1,2 (1.NHO Shikoku Cancer Center, 2.Ehime Cancer Medical Examination and Treatment Cooperation Conference, Cancer Registration Special Subcommittee)

[MO33-4] Impaired antibody response to mRNA vaccination for COVID-19 among patients with multiple myeloma

^○Sakuya Matsumoto¹, Kimikazu Yakushijin¹, Yohei Funakoshi¹, Goh Ohji², Wataru Hojo³, Hironori Sakai³, Marika Watanabe¹, Yu Mizutani¹, Akihito Kitao¹, Yoshiharu Miyata⁴, Yasuyuki Saito⁵, Shinichiro Kawamoto⁶, Katsuya Yamamoto¹, Mitsuhiro Ito⁷, Meiko Nishimura¹, Yoshinori Imamura¹, Naomi Kiyota^1,8, Hiroshi Matsuoka⁴, Yasuko Mori⁹, Hironobu Minami^1,8 (1.Division of Medical Oncology and Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, 2.DIvision of Infection Disease Therapeutics, Department of Microbiology and Infectious Diseases, Kobe University Hospital and Graduate School of Medicine, 3.R＆D, Cellspect Co., Ltd., Morioka, Iwate, Japan, 4.BioResource Center, Kobe University Hospital, 5.Division of Molecular and Cellular Signaling, Kobe University Graduate School of Medicine, 6.Department of Transfusion Medicine and Cell Therapy, Kobe University Hospital, 7.Division of Medical Biophysics, Kobe University Graduate School of Health Science, 8.Cancer Center, Kobe University Hospital, 9.Division of Clinical Virology, Canter for Infectious Diseases, Kobe University Graduate School of Medicine)

[MO33-5] Clinical investigation of the incidence of febrile neutropenia in inpatient chemotherapy under the COVID-19 epidemic

^○Hiroshi Yaegashi, Suguru Kadomoto, Iwamoto Hiroaki, Kouji Izumi, Atsushi Mizokami (Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science)

[MO33-6] Safety of anti SARS-CoV-2 Messenger RNA Vaccine for Patients with Advanced Lung Cancer Treated with Anti-cancer Drugs

^○Sayaka Tachibana¹, Koji Inoue¹, Tomoki Tamura², Kiichiro Ninomiya³, Toshio Kubo⁴, Shoichi Kuyama², Sayaka Tachibana¹, , Kenichi Chikamori⁵, Kenichiro Kudo⁶ , Nobuaki Ochi⁷, Daijiro Harada⁸, , Yoshinobu Maeda³, , Katsuyuki Kiura⁹ (1.Department of Respiratory Medicine, Ehime Prefectural Central Hospital, 2.Department of Respiratory Medicine, NHO Iwakuni Clinical Center, Iwakuni
3.Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, 4. Center for Clinical Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, 5. Department of Medical Oncology, National Hospital Organization Yamaguchi-Ube Medical Center, Ube, 6. Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center,Okayama, 7. General Internal Medicine 4, Kawasaki Medical School, Okayama, 8. Department of Thoracic Oncology, NHO Shikoku Cancer Center, Matsuyama, 9. Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama)